IMV Inc IMV-CA:Toronto Stock Exchange

*Data is delayed | CAD
Last | 09/24/21 EDT
2.19UNCH (UNCH)
52 week range
1.68 - 6.29
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.19
  • 52 Week High6.29
  • 52 Week High Date09/30/20
  • 52 Week Low1.68
  • 52 Week Low Date07/19/21

Key Stats

  • Market Cap117M
  • Shares Out67.8M
  • 10 Day Average Volume82,969.45
  • Dividend-
  • Dividend Yield-
  • Beta1.82
  • YTD % Change-43.7

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.19
  • 52 Week High6.29
  • 52 Week High Date09/30/20
  • 52 Week Low1.68
  • 52 Week Low Date07/19/21
  • Market Cap117M
  • Shares Out67.8M
  • 10 Day Average Volume82,969.45
  • Dividend-
  • Dividend Yield-
  • Beta1.82
  • YTD % Change-43.7

RATIOS/PROFITABILITY

  • EPS (TTM)-0.52
  • P/E (TTM)-4.22
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On IMV Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
IMV Inc. is a clinical stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases, including coronavirus disease 2019 (COVID-19). The Company develops cancer-targeted immunotherapies and vaccines based on the Company’s platform, DPX. The Company’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its T cell therapy is evaluated in phase II...
Andrew Sheldon
Non-Executive Chairman
Andrew Hall
Chief Executive Officer
Pierre Labbe CPA
Chief Financial Officer
Address
130 Eileen Stubbs Ave Suite 19
Dartmouth, NS
B3B 2C4
Canada

Top Peers

SYMBOLLASTCHG%CHG
ONC
EDSA
Edesa Biotech Inc
8.15-0.49-5.67%
MDNA
Medicenna Therapeutics Corp
2.55+0.07+2.62%
DMAC
DiaMedica Therapeutics Inc
3.92-0.17-4.16%
LMNL
Liminal BioSciences Inc
2.50-0.08-3.10%